ReviewPostepy psychiatrii neurologii2024
Ferroptosis as a potential connection between schizophrenia and metabolic dysfunction-associated steatotic liver disease - a narrative review.
Review in Postepy psychiatrii neurologii, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Concomitant pathologies and their impact on schizophrenia: a narrative overview of current evidence.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Mapping disease critical spatially variable gene programs by integrating spatial transcriptomics with human genetics.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Schizophrenia is a chronic condition that is associated with various comorbidities, including metabolic ones. Particular attention has been paid to the metabolic dysfunction-associated steatotic liver disease (MASLD), the liver equivalent of the metabolic syndrome. It is postulated that ferroptosis, a form of novel cell death connected with iron overload and lipid peroxidation, may be an interplaying factor in both of these conditions. This review aims to show the specific role of ferroptosis in the development and possible progression of MASLD among patients with schizophrenia. It will be accompanied by a consideration of the probable causes of the associations that occur. Views: Scientific reports suggest that there may be a genetic predisposition, in terms of ferroptosis, to the development of both schizophrenia and MASLD. Moreover, the role of poor dietary habits, specifically a high-fat diet and insufficient antioxidant intake, in excessive lipid peroxidation and iron overload is emphasized. Additionally, intestinal permeability, caused by iron overload, may contribute to a state of inflammation within the liver tissue. Finally, we cannot forget about the impact of antipsychotic drugs on the ferroptosis process - some of them may initiate this process through carbohydrate-lipid metabolism dysregulation, or causing hepatocyte iron overload, as well as disturbing cellular redox balance. Conclusions: The process of ferroptosis should be considered as one of the possible pathways which predispose a group of patients with schizophrenia to the development and progression of MASLD. Finding a possible marker of ferroptosis among the mentally ill population may be helpful in the identification of a subgroup of patients particularly vulnerable to steatotic liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.